Home › CTI BioPharma Corp (CTIC) Upgraded at Zacks Investment Research
 

Keywords :   


CTI BioPharma Corp (CTIC) Upgraded at Zacks Investment Research

2015-12-29 06:13:09| Biotech - Topix.net

The brokerage currently has a $1.50 price objective on the biopharmaceutical company's stock. Zacks Investment Research 's price target would indicate a potential upside of 16.28% from the stock's current price.

Tags: research investment corp upgraded

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
13.05HigherDoses New Red Light Hat Gives Hair Growth the Green Light
13.05Naturium Launches Glow Getter Body Oil Ahead of Summer 2024
13.05Aptoide sells stake in Faurecia Aptoide Automotive
13.05AppleTV+ fastest growing major SVOD service in Q1'24
13.05SafeShark finds connected devices not compliant with UK security law
13.05Zattoo deploys Bitmovin Player
13.05Altice USA residential video RGUs down 77,700 in 1Q 2024
13.05Fubo unveils new CTV ad offerings at 2024 IAB NewFronts
More »